PCM
CALA

Penserra Capital Management’s Calithera Biosciences, Inc CALA Stock Holding History

Penserra Capital Management’s Portfolio CALA Stock Details CALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-85
Closed -$3K – 1635
2021
Q3 		$3K Buy
85
+1
+1% +$43 ﹤0.01% 1432
2021
Q2 		$3K Buy
84
+4
+5% +$176 ﹤0.01% 1330
2021
Q1 		$3K Sell
80
-1
-1% -$58 ﹤0.01% 1099
2020
Q4 		$7K Buy
+81
New +$7.1K ﹤0.01% 963

Other funds holding CALA

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Penserra Capital Management's CALA Position: Q4 2021 in Review

Penserra Capital Management sold out of Calithera Biosciences, Inc (CALA) in Q4 2021, closing a stake of 85 shares — an estimated $3K sold.

Penserra Capital Management first reported a position in CALA in Q4 2020 and held it in 4 quarters. The position peaked at $7K in Q4 2020. 55 funds tracked by Wall St. Rank hold CALA as of Q4 2021.

  • Penserra Capital Management reported no remaining Calithera Biosciences, Inc position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 85 Calithera Biosciences, Inc shares in Q4 2021, an estimated $3K.
  • Penserra Capital Management first reported a position in Calithera Biosciences, Inc in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's Calithera Biosciences, Inc position peaked at $7K in Q4 2020.
  • 55 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.